American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
Portfolio Pulse from
Phio Pharmaceuticals Corp. presented interim results of its clinical study on PH-762 for cutaneous carcinomas at the American Academy of Dermatology's 2025 Annual Meeting. The presentation was part of the Late-Breaking Research session, highlighting the potential of Phio's INTASYL® siRNA gene silencing technology.
March 10, 2025 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phio Pharmaceuticals presented interim results for its lead product candidate, PH-762, at a prestigious dermatology conference, potentially boosting investor confidence in its innovative cancer treatment technology.
The presentation of interim results at a major dermatology conference suggests positive progress in Phio's clinical research, which could enhance investor sentiment and lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100